Impact of inflammatory bowel disease and ursodeoxycholic acid theraphy on small-duct primary sclerosing cholangitis

Phunchai Charatcharoenwitthaya, Paul Angulo, Felicity T Enders, Keith D. Lindor

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

A longitudinal, cohort study was performed to characterize the clinical features of patients with small-duct primary sclerosing cholangitis (PSC) occurring with and without inflammatory bowel disease (IBD) and to determine the influence of IBD and the effect of ursodeoxycholic acid (UDCA) therapy on the course of the liver disease. Forty-two patients with small-duct PSC (14 women and 28 men; mean age, 36.7 ± 13.3 years) were followed for up to 24.9 years. At presentation, prevalence of signs of liver disease (none versus 35%, P = 0.002), gastroesophageal varices (5% versus 30%, P = 0.03), and stage III/IV disease (9% versus 45%, P = 0.008) were lower in those with IBD versus those without IBD. During follow-up, 6 patients underwent liver transplantation, and another died of cirrhosis. Using the Cox proportional hazard analysis, concomitant IBD was not associated with liver death or transplant, whereas the revised Mayo risk score for PSC was the only prognostic factor associated with liver-related outcomes (relative risk, 6.47; 95% confidence interval, 1.75-137.5). UDCA (13-15 mg/kg/day) therapy for an average of 40 months showed biochemical improvement (P < 0.001) in UDCA-treated patients, while no significant change occurred in untreated patients. UDCA therapy had no effect on delaying progression of disease (relative risk, 0.95; 95% confidence interval, 0.38-2.36). Conclusion: Small-duct PSC often is recognized at an early stage in patients with IBD; however, IBD has no impact on long-term prognosis. Although UDCA therapy improves liver biochemistries, it may not delay disease progression during the short period of treatment.

Original languageEnglish (US)
Pages (from-to)133-142
Number of pages10
JournalHepatology
Volume47
Issue number1
DOIs
StatePublished - Jan 2008

Fingerprint

Ursodeoxycholic Acid
Sclerosing Cholangitis
Inflammatory Bowel Diseases
Disease Progression
Liver Diseases
Liver
Confidence Intervals
Therapeutics
Varicose Veins
Biochemistry
Liver Transplantation
Longitudinal Studies
Fibrosis
Cohort Studies
Transplants

ASJC Scopus subject areas

  • Hepatology

Cite this

Impact of inflammatory bowel disease and ursodeoxycholic acid theraphy on small-duct primary sclerosing cholangitis. / Charatcharoenwitthaya, Phunchai; Angulo, Paul; Enders, Felicity T; Lindor, Keith D.

In: Hepatology, Vol. 47, No. 1, 01.2008, p. 133-142.

Research output: Contribution to journalArticle

Charatcharoenwitthaya, Phunchai ; Angulo, Paul ; Enders, Felicity T ; Lindor, Keith D. / Impact of inflammatory bowel disease and ursodeoxycholic acid theraphy on small-duct primary sclerosing cholangitis. In: Hepatology. 2008 ; Vol. 47, No. 1. pp. 133-142.
@article{0d4e3821e18d403fb84ac0d71d8eb4b8,
title = "Impact of inflammatory bowel disease and ursodeoxycholic acid theraphy on small-duct primary sclerosing cholangitis",
abstract = "A longitudinal, cohort study was performed to characterize the clinical features of patients with small-duct primary sclerosing cholangitis (PSC) occurring with and without inflammatory bowel disease (IBD) and to determine the influence of IBD and the effect of ursodeoxycholic acid (UDCA) therapy on the course of the liver disease. Forty-two patients with small-duct PSC (14 women and 28 men; mean age, 36.7 ± 13.3 years) were followed for up to 24.9 years. At presentation, prevalence of signs of liver disease (none versus 35{\%}, P = 0.002), gastroesophageal varices (5{\%} versus 30{\%}, P = 0.03), and stage III/IV disease (9{\%} versus 45{\%}, P = 0.008) were lower in those with IBD versus those without IBD. During follow-up, 6 patients underwent liver transplantation, and another died of cirrhosis. Using the Cox proportional hazard analysis, concomitant IBD was not associated with liver death or transplant, whereas the revised Mayo risk score for PSC was the only prognostic factor associated with liver-related outcomes (relative risk, 6.47; 95{\%} confidence interval, 1.75-137.5). UDCA (13-15 mg/kg/day) therapy for an average of 40 months showed biochemical improvement (P < 0.001) in UDCA-treated patients, while no significant change occurred in untreated patients. UDCA therapy had no effect on delaying progression of disease (relative risk, 0.95; 95{\%} confidence interval, 0.38-2.36). Conclusion: Small-duct PSC often is recognized at an early stage in patients with IBD; however, IBD has no impact on long-term prognosis. Although UDCA therapy improves liver biochemistries, it may not delay disease progression during the short period of treatment.",
author = "Phunchai Charatcharoenwitthaya and Paul Angulo and Enders, {Felicity T} and Lindor, {Keith D.}",
year = "2008",
month = "1",
doi = "10.1002/hep.21960",
language = "English (US)",
volume = "47",
pages = "133--142",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "1",

}

TY - JOUR

T1 - Impact of inflammatory bowel disease and ursodeoxycholic acid theraphy on small-duct primary sclerosing cholangitis

AU - Charatcharoenwitthaya, Phunchai

AU - Angulo, Paul

AU - Enders, Felicity T

AU - Lindor, Keith D.

PY - 2008/1

Y1 - 2008/1

N2 - A longitudinal, cohort study was performed to characterize the clinical features of patients with small-duct primary sclerosing cholangitis (PSC) occurring with and without inflammatory bowel disease (IBD) and to determine the influence of IBD and the effect of ursodeoxycholic acid (UDCA) therapy on the course of the liver disease. Forty-two patients with small-duct PSC (14 women and 28 men; mean age, 36.7 ± 13.3 years) were followed for up to 24.9 years. At presentation, prevalence of signs of liver disease (none versus 35%, P = 0.002), gastroesophageal varices (5% versus 30%, P = 0.03), and stage III/IV disease (9% versus 45%, P = 0.008) were lower in those with IBD versus those without IBD. During follow-up, 6 patients underwent liver transplantation, and another died of cirrhosis. Using the Cox proportional hazard analysis, concomitant IBD was not associated with liver death or transplant, whereas the revised Mayo risk score for PSC was the only prognostic factor associated with liver-related outcomes (relative risk, 6.47; 95% confidence interval, 1.75-137.5). UDCA (13-15 mg/kg/day) therapy for an average of 40 months showed biochemical improvement (P < 0.001) in UDCA-treated patients, while no significant change occurred in untreated patients. UDCA therapy had no effect on delaying progression of disease (relative risk, 0.95; 95% confidence interval, 0.38-2.36). Conclusion: Small-duct PSC often is recognized at an early stage in patients with IBD; however, IBD has no impact on long-term prognosis. Although UDCA therapy improves liver biochemistries, it may not delay disease progression during the short period of treatment.

AB - A longitudinal, cohort study was performed to characterize the clinical features of patients with small-duct primary sclerosing cholangitis (PSC) occurring with and without inflammatory bowel disease (IBD) and to determine the influence of IBD and the effect of ursodeoxycholic acid (UDCA) therapy on the course of the liver disease. Forty-two patients with small-duct PSC (14 women and 28 men; mean age, 36.7 ± 13.3 years) were followed for up to 24.9 years. At presentation, prevalence of signs of liver disease (none versus 35%, P = 0.002), gastroesophageal varices (5% versus 30%, P = 0.03), and stage III/IV disease (9% versus 45%, P = 0.008) were lower in those with IBD versus those without IBD. During follow-up, 6 patients underwent liver transplantation, and another died of cirrhosis. Using the Cox proportional hazard analysis, concomitant IBD was not associated with liver death or transplant, whereas the revised Mayo risk score for PSC was the only prognostic factor associated with liver-related outcomes (relative risk, 6.47; 95% confidence interval, 1.75-137.5). UDCA (13-15 mg/kg/day) therapy for an average of 40 months showed biochemical improvement (P < 0.001) in UDCA-treated patients, while no significant change occurred in untreated patients. UDCA therapy had no effect on delaying progression of disease (relative risk, 0.95; 95% confidence interval, 0.38-2.36). Conclusion: Small-duct PSC often is recognized at an early stage in patients with IBD; however, IBD has no impact on long-term prognosis. Although UDCA therapy improves liver biochemistries, it may not delay disease progression during the short period of treatment.

UR - http://www.scopus.com/inward/record.url?scp=38649126544&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38649126544&partnerID=8YFLogxK

U2 - 10.1002/hep.21960

DO - 10.1002/hep.21960

M3 - Article

VL - 47

SP - 133

EP - 142

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 1

ER -